Angiotensin 1-7 in severe COVID-19 patients: a phase 1 clinical trial

Martins, Ana Luiza Valle; Annoni, Filippo; Silva, Filipe Alex da; Bolais-Ramos, Lucas; Oliveira, Gisele Capanema de; Matos, Alana Helen dos Santos; Heyden, Maria Cecilia Jardim; Pinheiro, Beatriz Dias; Rodrigues, Natalia Abdo; Pereira, Danilo Augusto Alves; Diniz, Mirella Monique Lana; Silva, Thuanny Granato Fonseca; Cardoso, Alexandre Carvalho; Martins, Juliana Carvalho; Motta‐Santos, Daisy; Campagnole‐Santos, Maria José; Verano‐Braga, Thiago; Taccone, Fabio Silvio; Santos, Robson A.S.

doi:10.1101/2022.09.15.22279897

Cited by 1 publication

(1 citation statement)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In confirmed COVID-19 patients, the effects of plasma with Ang-(1–7) were evaluated, observing an improvement in the clinical status of the patient ( Onal et al, 2022 ). Importantly, two independent pilot clinical trials aimed to determine the safety of human use of TXA-127 [a pharmaceutically formulated Ang-(1–7)] ( Wagener et al, 2022 ), or Ang-(1–7) ( Valle Martins et al, 2022 ) delivered these peptides intravenously to COVID-19 patients, showing a safe use of both molecules, and suggesting the potential clinical use as treatment for severe COVID-19.…”

Section: Translational Relevancementioning

confidence: 99%

Counter-regulatory RAS peptides: new therapy targets for inflammation and fibrotic diseases?

Ávila-Martínez,

Mixtega-Ruiz,

Hurtado-Capetillo

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

The renin-angiotensin system (RAS) is an important cascade of enzymes and peptides that regulates blood pressure, volume, and electrolytes. Within this complex system of reactions, its counter-regulatory axis has attracted attention, which has been associated with the pathophysiology of inflammatory and fibrotic diseases. This review article analyzes the impact of different components of the counter-regulatory axis of the RAS on different pathologies. Of these peptides, Angiotensin-(1–7), angiotensin-(1–9) and alamandine have been evaluated in a wide variety of in vitro and in vivo studies, where not only they counteract the actions of the classical axis, but also exhibit independent anti-inflammatory and fibrotic actions when binding to specific receptors, mainly in heart, kidney, and lung. Other functional peptides are also addressed, which despite no reports associated with inflammation and fibrosis to date were found, they could represent a potential target of study. Furthermore, the association of agonists of the counter-regulatory axis is analyzed, highlighting their contribution to the modulation of the inflammatory response counteracting the development of fibrotic events. This article shows an overview of the importance of the RAS in the resolution of inflammatory and fibrotic diseases, offering an understanding of the individual components as potential treatments.

show abstract

Section: Translational Relevancementioning

confidence: 99%